US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Dick Taylor Craft Chocolate Issues Recall for Allergy Allert on Undeclared Peanuts in “Ginger Snap Milk Chocolate”

      Summary Company Announcement Date: September 28, 2023 FDA Publish Date: … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Food Recalls / FDA Press Releases / FDA Alert: New USP Standards for Heparin Products Will Result in Decreased Potency

FDA Alert: New USP Standards for Heparin Products Will Result in Decreased Potency

October 2, 2009 By The FDA 1 Comment

The U.S. Food and Drug Administration (FDA) is alerting healthcare providers of a change to the United States Pharmacopeia (USP) monograph for heparin, effective October 1, 2009.  Manufacturers will not begin shipping heparin products manufactured and tested according to the new USP monograph until October 8th or later. This change—largely in response to the 2007-2008 heparin contamination problem—will include a new USP reference standard and test method that is used to determine the potency of the drug. The new test method, unlike the previous method, is able to detect impurities that may be present in heparin. The monograph change will also harmonize the USP unit dose with the WHO International Standard (IS) unit dose.

The manufacturing and testing requirements under the new monograph will lessen the potential for contamination of heparin and enhance the production of a high quality drug.  However, harmonization of the standard will result in approximately a 10% reduction in the potency of the heparin marketed in the United States.

The change in heparin potency may have clinical significance in some situations, such as when heparin is administered as a bolus intravenous dose and an immediate anticoagulant effect is clinically important.  In such situations healthcare providers should consider the change in potency of heparin when making decisions about what dose to administer.  The change in heparin potency is expected to be less clinically significant when it is administered subcutaneously due to the low and highly variable bioavailability of heparin when administered by this route.  Healthcare providers should also be aware of the decrease in heparin potency as they monitor the anticoagulant effect of the drug; more heparin may be required to achieve and maintain the desired level of anticoagulation in some patients. 

Healthcare providers should be aware of the potency change for heparin products manufactured and tested according to the new USP monograph, and the possible clinical effects of this decrease in potency per USP unit dose.

FDA has asked all manufacturers to label their new products in a manner that will help healthcare providers differentiate them from the old products. Labels of most heparin products made according to the new standard will have an “N” in the lot number or following the expiration date. Products manufactured by Hospira can be identified by the number “82” or higher (e.g., 83, 84) at the start of their lot numbers.

The USP is an official standards setting organization for prescription and over–the–counter (OTC) medicines sold in the United States. USP sets standards for the quality, purity, strength, and consistency of medicinal products.

FDA wants to highlight some important information and clinical recommendations during this time of transition:

  • There will be simultaneous availability of heparin manufactured to meet the “old” and “new” USP monograph, with potential differences in potency.  This overlap of products on the market is necessary to make certain that there is an adequate supply of heparin available for all patients. Products using the new “USP unit” potency definition are anticipated to be available on or after October 8.  FDA is working with the manufacturers of heparin to ensure that an appropriate identifier is placed on heparin made under the new USP monograph. Most manufacturers will place an “N” next to the lot number.
  • Consider the potential potency variation when administering heparin, particularly in situations where assurance of aggressive anticoagulation is essential to treat or prevent life-threatening thromboses. Clinicians should now consider the potential for up to 10% estimated decrease in heparin activity per “USP unit” when deciding what dose to administer in such cases.  
  • The potency change may require more frequent or intensive aPTT or ACT monitoring.
  • Clinical judgment is essential in determining dose of heparin.  Heparin dosing is always individualized to the patient-specific situation. The FDA-approved labeling for heparin has not changed, including the recommended doses.  Individualization of heparin dosing has long been the standard for clinical use of the drug and FDA reiterates the importance of clinical judgment in heparin dosing.

FDA is working with the heparin manufacturers to study the impact of this variation in potency and will make the results available when the studies have concluded.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: FDA Press Releases

About The FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods and Veterinary Medicine, Global Regulatory Operations and Policy, and Operations.

Comments

  1. nursat Aygen says

    October 9, 2009 at 12:24 pm

    When will Heparin be available again?Please letme know.
    Thank you.
    N Aygen

    Reply

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Dick Taylor Craft Chocolate Issues Recall for Allergy Allert on Undeclared Peanuts in “Ginger Snap Milk Chocolate”

September 27, 2023 By The FDA

Penzeys Spices Issues Allergy Alert on Undeclared Sesame Seeds in “Brady Street Cheese Sprinkle”

September 27, 2023 By The FDA

Trek Recalls Allant+ 7 Bicycles Due to Crash Hazard

September 27, 2023 By The CPSC

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Rust-Oleum Recalls Fluorescent Pink Spray Paint Due to Injury Hazard

September 27, 2023 By The CPSC

Secura Recalls Air Fryers Due to Fire and Burn Hazards (Recall Alert)

September 27, 2023 By The CPSC

Polaris Recalls Ranger Recreational Off-Highway Vehicles and Pro XD Utility Vehicles, Gravely ATLAS Utility Vehicles, and Bobcat Utility Vehicles Due to Injury Hazard (Recall Alert)

September 27, 2023 By The CPSC

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non-Antibacterial ßlactam Drug Substance

September 26, 2023 By The FDA

Eagle Produce LLC Recalls Whole Cantaloupe Because of Possible Health Risk

September 26, 2023 By The FDA

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non-Antibacterial ßlactam Drug Substance

September 26, 2023 By The FDA

Eagle Produce LLC Recalls Whole Cantaloupe Because of Possible Health Risk

September 26, 2023 By The FDA

Safeway Fresh Foods Recalls Sunnyside Farms Organic Butternut Squash Because of Possible Health Risk

September 24, 2023 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Dick Taylor Craft Chocolate Issues Recall for Allergy Allert on Undeclared Peanuts in “Ginger Snap Milk Chocolate”
  • Penzeys Spices Issues Allergy Alert on Undeclared Sesame Seeds in “Brady Street Cheese Sprinkle”
  • Trek Recalls Allant+ 7 Bicycles Due to Crash Hazard
  • Procter & Gamble Recalls Zevo Fly, Gnat and Fruit Fly Insect Spray Due to Injury and Laceration Hazards
  • Nutraceutical Recalls Solaray Liposomal Multivitamins Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning
  • Rust-Oleum Recalls Fluorescent Pink Spray Paint Due to Injury Hazard
  • Secura Recalls Air Fryers Due to Fire and Burn Hazards (Recall Alert)
  • Polaris Recalls Ranger Recreational Off-Highway Vehicles and Pro XD Utility Vehicles, Gravely ATLAS Utility Vehicles, and Bobcat Utility Vehicles Due to Injury Hazard (Recall Alert)
  • SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non-Antibacterial ßlactam Drug Substance
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in